Esperion Therapeutics Inc. is set to participate in the Jefferies Global Healthcare Conference in New York on June 4, 2025, at 1:25 p.m. ET. The company, a leading biopharmaceutical firm, will be showcasing its advancements in developing FDA-approved oral, non-statin medicines aimed at patients at risk for cardiovascular disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.